Posts by tag
value
Unpaid women carers: recognising their contribution and their needs in Latin America
Researchers and public policies have historically overlooked the challenges of informal caregiving for cancer patients in Latin America. Now, public health experts are working to profile this neglected group, evaluate their quality of life and put an economic value on…
Does it work for my patient? A pragmatic approach to building evidence on clinical effectiveness
Should patients be at the centre of attention in the development of new cancer drugs? It might seem extraordinary that this question is even asked – what else matters? But it is a question high on the agenda of the…
Real world data: can we rely on it to shape cancer policies and practice?
In November 2018, the US Food and Drug Administration granted accelerated approval to larotrectinib (Vitrakvi), a drug that targets a neurotrophic receptor tyrosine kinase (NTRK) gene fusion in a range of adult and paediatric tumours. European approval followed last autumn.…